PitchSend

Investor Presentaiton

Investor presentation Full year 2018 Slide 24 Sales growth driven by the diabetes and obesity franchise Novo Nordisk reported quarterly sales by therapy Reported sales split by product segments for full year 2018 Premix insulin Fast-acting insulin Diabetes and obesity Haemophilia² bDKK NorditropinⓇ Other Long-acting insulin Human insulin 35 Growth disorders Reported sales CAGR¹: 9.0% 30 25 -2.1% 20 6.6% 15 3.2% 10.5% 10 5 0 Q4 2008 1 CAGR for 10-year period 2 Haemophilia comprises NovoSeven®, NovoThirteen®, Novo Eight® and Refixia® changing diabetes Q4 2018 GLP-1 Haemophilia 1% 6% 19% 9% 7% Other diabetes and obesity Other biopharmaceuticals 9% 23% 17% 8% Sales of DKK 111.8 billion (0%) Note: Numbers do not add up to 100 due to rounding novo nordisk

View entire presentation